MD Biologix named one of Canada's Top Growing Companies, ranking No. 38 in Health Care & Wellness

MD Biologix earns a place on The Globe and Mail's eighth annual ranking for the first time

---

TORONTO, ONTARIO — MD Biologix has been named one of Canada's Top Growing Companies by The Globe and Mail’s Report on Business magazine, earning a place on the 2026 ranking for the first time in the company's history. The company ranks No. 38 in the Health Care & Wellness category, with three-year revenue growth of 51%.

MD Biologix is a family-owned Canadian distributor of regenerative medicine technologies — including KeyPRP™ platelet-rich plasma (PRP) systems and Synolis VA hyaluronic acid (HA) injections — serving sports medicine, physiatry, and orthopaedic practitioners across Canada. The company was the first to bring point-of-care autologous cell therapy to Canadians.

“Making this list for the first time is a milestone for our team, and a clear signal of where musculoskeletal care in Canada is heading,” said Connor Downs, President of MD Biologix.   

“Clinicians and their patients are increasingly choosing non-surgical options that help the body heal itself, and we’ve grown by giving practitioners the tools to deliver that care with confidence. This recognition belongs to our team and to the clinical partners who trust us to support their patients. And we’re just getting started.” 

Canada's Top Growing Companies is an editorial ranking that launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this program, companies voluntarily completed an in-depth application process and fulfilled targeted revenue requirements. In total, 376 companies earned a spot on this year's ranking.

The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here: https://www.theglobeandmail.com/business/rob-magazine/top-growing-companies/article-ranking-canadas-top-growing-companies-of-2026/

“Our annual ranking of Canada's Top Growing Companies celebrates the innovation, ambition and resilience of businesses across the country, and we're always excited to share as many of these standout stories as we can—including insight from the entrepreneurs themselves on how other companies can succeed, too,” said Dawn Calleja, editor of Report on Business magazine.

“The Globe and Mail congratulates the winners of Canada's Top Growing Companies 2026 on this exceptional achievement,” said Andrew Saunders, president and CEO of The Globe and Mail.   

“Each of these organizations has shown an extraordinary ability to adapt, innovate and grow amid ongoing change. Their achievements reflect the ingenuity and determination of Canadian entrepreneurs and business leaders who are helping shape the future of our economy.”

About The Globe and Mail

The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About MD Biologix

MD Biologix is a privately held, family-run Canadian distributor of autologous biologics and regenerative medicine technologies for healthcare practitioners. The first company to bring point-of-care autologous cell therapy to Canadians, MD Biologix supplies a focused portfolio including KeyPRP™, Synolis VA, LipoPro™ and Marrow Cellutions™ to clinics nationwide. The company holds a Health Canada Medical Device Establishment Licence and is based in Toronto, Ontario. Learn more at www.mdbiologix.com.

Media contact

Justin Tomkin, Business Development and Marketing · info@mdbiologix.com · (437) 524-0834